Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.60 |
| ▸ | SOS1 | Q07889 | 11/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL405070 | 0.95 | HRH4 (0.60) | HRH4SOS1HTR6ADRB1NCF1 | |
| SCHEMBL405985 | 0.93 | HRH4 (0.62) | HRH4SOS1HTR6ADRB1CHRNB2 | |
| SCHEMBL404669 | 0.86 | HRH4 (0.59) | HRH4SOS1 | |
| SCHEMBL405989 | 0.86 | HRH4 (0.57) | HRH4SOS1HTR6 | |
| SCHEMBL404682 | 0.85 | HRH4 (0.54) | HRH4SOS1HTR6ADRB1NCF1 | |
| SCHEMBL438079 | 0.85 | HRH4 (0.54) | HRH4SOS1HTR6 | |
| SCHEMBL406130 | 0.83 | HRH4 (0.66) | HRH4SOS1HTR6NCF1 | |
| SCHEMBL406287 | 0.83 | HRH4 (0.54) | HRH4SOS1HTR6ADRB1NCF1 | |
| SCHEMBL404525 | 0.83 | HRH4 (0.63) | HRH4SOS1NCF1 | |
| SCHEMBL462813 | 0.83 | HRH4 (0.54) | HRH4SOS1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HRH4 1/4885SOS1 3564/4885HTR6 111/4885 |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HRH4 1/4885SOS1 3564/4885HTR6 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.